EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model

Antibody-Dependent Cell-Mediated Cytotoxicity Effector-Enhanced EphA2 Agonist Monoclonal Antibody Demonstrates Potent Activity against Human Tumors

(2015) Elizabeth M. Bruckheimer et al.   NEOPLASIA

Enhancement in Specific CD8+ T Cell Recognition of EphA2+ Tumors In Vitro and In Vivo after Treatment with Ligand Agonists

(2014) A. K. Wesa et al.   JOURNAL OF IMMUNOLOGY

Targeted lung cancer therapy using ephrinA1-loaded albumin microspheres

(2011) Hung-Yen Lee et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Combined Flt3L/TK Gene Therapy Induces Immunological Surveillance Which Mediates an Immune Response Against a Surrogate Brain Tumor Neoantigen

(2011) Gwendalyn D King et al.   MOLECULAR THERAPY

Eph/Ephrin Profiling in Human Breast Cancer Reveals Significant Associations between Expression Level and Clinical Outcome

(2011) Dana M. Brantley-Sieders et al.   PLoS One

Sequential administration of bovine and human adenovirus vectors to overcome vector immunity in an immunocompetent mouse model of breast cancer

(2011) Manish Tandon et al.   VIRUS RESEARCH

Emerging strategies for EphA2 receptor targeting for cancer therapeutics

(2010) Manish Tandon et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Evaluation of cross-reactive cell-mediated immune responses among human, bovine and porcine adenoviruses

(2010) A Sharma et al.   GENE THERAPY

Mechanisms regulating dendritic cell specification and development

(2010) Stephanie S. Watowich et al.   IMMUNOLOGICAL REVIEWS

A Novel Bicistronic High-Capacity Gutless Adenovirus Vector That Drives Constitutive Expression of Herpes Simplex Virus Type 1 Thymidine Kinase and Tet-Inducible Expression of Flt3L for Glioma Therapeutics

(2010) M. Puntel et al.   JOURNAL OF VIROLOGY

Evaluation of innate immunity and vector toxicity following inoculation of bovine, porcine or human adenoviral vectors in a mouse model

(2010) Anurag Sharma et al.   VIRUS RESEARCH

The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer

(2009) C Horlock et al.   BRITISH JOURNAL OF CANCER

Elevation of Receptor Tyrosine Kinase EphA2 Mediates Resistance to Trastuzumab Therapy

(2009) G. Zhuang et al.   CANCER RESEARCH

Antiglioma Immunological Memory in Response to Conditional Cytotoxic/Immune-Stimulatory Gene Therapy: Humoral and Cellular Immunity Lead to Tumor Regression

(2009) A.K.M. Ghulam Muhammad et al.   CLINICAL CANCER RESEARCH

EphA2 Immunoconjugate as Molecularly Targeted Chemotherapy for Ovarian Carcinoma

(2009) Jeong-Won Lee et al.   JNCI-Journal of the National Cancer Institute

Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model

(2009) Anurag Sharma et al.   VIROLOGY

HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor Regression

(2009) James F Curtin et al.   PLOS MEDICINE

The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling

(2008) Dana M. Brantley-Sieders et al.   JOURNAL OF CLINICAL INVESTIGATION

The EphA2 Receptor and EphrinA1 Ligand in Solid Tumors: Function and Therapeutic Targeting

(2008) J. Wykosky et al.   MOLECULAR CANCER RESEARCH

Flt3L in Combination With HSV1-TK-mediated Gene Therapy Reverses Brain Tumor–induced Behavioral Deficits

(2008) Gwendalyn D King et al.   MOLECULAR THERAPY

Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands

(2008) M. Campoli et al.   TISSUE ANTIGENS

Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model

(2007) Gwendalyn D. King et al.   NEURO-ONCOLOGY